Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2018 16:05 ET | Source: KemPharm

KemPharm, Inc. Reports Second Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced top line results from KP415.E01 efficacy and safety trial in...
August 01, 2018 07:30 ET | Source: KemPharm

KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference

CORALVILLE, Iowa, Aug. 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today...
July 31, 2018 07:30 ET | Source: KemPharm

KemPharm, Inc. to Report Second Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for August 9, 2018, 4:30 p.m. ET CORALVILLE, Iowa, July 31, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a...
July 09, 2018 07:00 ET | Source: KemPharm

KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD

Results from Single Classroom-Style Trial Met Pre-Specified Primary and Secondary Endpoints Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 8:00 a.m. ET ...
May 10, 2018 16:05 ET | Source: KemPharm

KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Intravenous Human Abuse Potential Trial with KP415 Prodrug (KP415.A03) Clinical Findings: Following...
May 01, 2018 07:30 ET | Source: KemPharm

KemPharm, Inc. to Report First Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for May 10, 2018, 4:30 p.m. ET CORALVILLE, Iowa, May 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty...
March 29, 2018 16:05 ET | Source: KemPharm

KemPharm Reports Fourth Quarter and Year End 2017 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: FDA Approval Announced of APADAZ™ (benzhydrocodone and...
March 21, 2018 07:30 ET | Source: KemPharm

KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for March 29th, 2018, 4:30 p.m. ET CORALVILLE, Iowa, March 21, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a...
March 20, 2018 07:30 ET | Source: KemPharm

KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD

Results Suggest that Data from Single Classroom-style Efficacy Study May Be Applicable Across Pediatric, Adolescent and Adult ADHD Patient Populations CORALVILLE, Iowa, March 20, 2018 (GLOBE...
March 06, 2018 07:30 ET | Source: KemPharm

KemPharm to Present at Upcoming Investor Conferences

Presentations to Highlight Corporate and Clinical Progress CORALVILLE, Iowa, March 06, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the...